title: Multigene prognostic tests in breast cancer: past, present, future.
abstract: There is growing consensus that multigene prognostic tests provide useful complementary information to tumor size and grade in estrogen receptor (ER)-positive breast cancers. The tests primarily rely on quantification of ER and proliferation-related genes and combine these into multivariate prediction models. Since ER-negative cancers tend to have higher proliferation rates, the prognostic value of current multigene tests in these cancers is limited. First-generation prognostic signatures (Oncotype DX, MammaPrint, Genomic Grade Index) are substantially more accurate to predict recurrence within the first 5 years than in later years. This has become a limitation with the availability of effective extended adjuvant endocrine therapies. Newer tests (Prosigna, EndoPredict, Breast Cancer Index) appear to possess better prognostic value for late recurrences while also remaining predictive of early relapse. Some clinical prediction problems are more difficult to solve than others: there are no clinically useful prognostic signatures for ER-negative cancers, and drug-specific treatment response predictors also remain elusive. Emerging areas of research involve the development of immune gene signatures that carry modest but significant prognostic value independent of proliferation and ER status and represent candidate predictive markers for immune-targeted therapies. Overall metrics of tumor heterogeneity and genome integrity (for example, homologue recombination deficiency score) are emerging as potential new predictive markers for platinum agents. The recent expansion of high-throughput technology platforms including low-cost sequencing of circulating and tumor-derived DNA and RNA and rapid reliable quantification of microRNA offers new opportunities to build extended prediction models across multiplatform data.
authors.forename: Balázs
authors.initials: B
authors.lastname: Győrffy
authors.forename: Christos
authors.initials: C
authors.lastname: Hatzis
authors.forename: Tara
authors.initials: T
authors.lastname: Sanft
authors.forename: Erin
authors.initials: E
authors.lastname: Hofstatter
authors.forename: Bilge
authors.initials: B
authors.lastname: Aktas
authors.forename: Lajos
authors.initials: L
authors.lastname: Pusztai
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000235:genetics* / Q000378:metabolism; D001943:Breast Neoplasms / Q000175:diagnosis* / Q000188:drug therapy / Q000235:genetics* / Q000378:metabolism; D005260:Female; D020869:Gene Expression Profiling / Q000379:methods*; D005820:Genetic Testing / Q000379:methods*; D006801:Humans; D007150:Immunohistochemistry / Q000379:methods; D009364:Neoplasm Recurrence, Local; D011379:Prognosis; D016896:Treatment Outcome
chemical_list: D014408:Biomarkers, Tumor
references.citation: Mod Pathol. 2013 May;26(5):658-64
references.pmid: 23503643
references.citation: Br J Cancer. 2012 Nov 6;107(10):1776-82
references.pmid: 23047548
references.citation: Breast Cancer Res Treat. 2009 Jul;116(2):295-302
references.pmid: 18661261
references.citation: J Clin Oncol. 2013 Aug 1;31(22):2783-90
references.pmid: 23816962
references.citation: BMC Bioinformatics. 2011;12:463
references.pmid: 22132775
references.citation: Clin Cancer Res. 2011 Sep 15;17(18):6012-20
references.pmid: 21807638
references.citation: J Clin Oncol. 2011 Nov 10;29(32):4273-8
references.pmid: 21990413
references.citation: Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8418-23
references.pmid: 12829800
references.citation: BMC Genomics. 2009;10:424
references.pmid: 19744330
references.citation: J Clin Oncol. 2007 Nov 20;25(33):5287-312
references.pmid: 17954709
references.citation: Breast Cancer Res. 2011;13(5):R98
references.pmid: 21999244
references.citation: J Clin Oncol. 2008 Mar 10;26(8):1275-81
references.pmid: 18250347
references.citation: Breast Cancer Res Treat. 2011 Nov;130(1):155-64
references.pmid: 21833625
references.citation: JAMA. 2011 May 11;305(18):1873-81
references.pmid: 21558518
references.citation: Cancer Discov. 2012 Apr;2(4):366-75
references.pmid: 22576213
references.citation: Ann Oncol. 2013 Mar;24(3):640-7
references.pmid: 23035151
references.citation: J Clin Oncol. 2006 Aug 10;24(23):3726-34
references.pmid: 16720680
references.citation: Lancet Oncol. 2013 Oct;14(11):1067-76
references.pmid: 24035531
references.citation: Oncologist. 2012;17(4):492-8
references.pmid: 22418568
references.citation: N Engl J Med. 2004 Dec 30;351(27):2817-26
references.pmid: 15591335
references.citation: Clin Cancer Res. 2008 May 1;14(9):2601-8
references.pmid: 18451222
references.citation: Int J Cancer. 2013 Aug 15;133(4):929-36
references.pmid: 23371464
references.citation: N Engl J Med. 2009 Feb 19;360(8):790-800
references.pmid: 19228622
references.citation: PLoS One. 2013 Jun 27;8(6):e68252
references.pmid: 23826382
references.citation: Breast Cancer Res Treat. 2010 Apr;120(3):655-61
references.pmid: 20204499
references.citation: J Natl Cancer Inst. 2006 Feb 15;98(4):262-72
references.pmid: 16478745
references.citation: J Clin Oncol. 2013 Mar 1;31(7):860-7
references.pmid: 23341518
references.citation: N Engl J Med. 2002 Dec 19;347(25):1999-2009
references.pmid: 12490681
references.citation: PLoS One. 2011;6(2):e17163
references.pmid: 21347257
references.citation: Ann Oncol. 2012 Nov;23(11):2866-73
references.pmid: 22532584
references.citation: J Clin Oncol. 2010 Oct 1;28(28):4316-23
references.pmid: 20805453